ITOS
iTeos Therapeutics, Inc. [ITOS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ITOS Stock Summary
Top 10 Correlated ETFs
ITOS
Top 10 Correlated Stocks
ITOS
In the News
ITOS Financial details
Company Rating
-
Market Cap
420.08M
Income
-112.64M
Revenue
12.6M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
157
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-6.58
Forward P/E
-
PEG
0.3
P/S
6.1
P/B
0.68
P/C
-
P/FCF
-3.41
Quick Ratio
21.45
Current Ratio
21.94
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.15
EPS next Y
-
EPS next Q
-
EPS this Y
-215.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-5.56%
-
-
-
-
SMA20
16.67%
SMA50
-
SMA100
-12.5%
Inst Own
-
Inst Trans
-
ROA
-9%
ROE
-10%
ROC
-0.14%
Gross Margin
100%
Oper. Margin
-141%
Profit Margin
-93%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.2-18.24
52W High
-60.19%
52W Low
-10.44%
RSI
56
Rel Volume
0.92
Avg Volume
280.8K
Volume
257.92K
Perf Week
-3.83%
Perf Month
2.95%
Perf Quarter
-22.29%
Perf Half Y
-19.76%
-
-
-
-
Beta
1.194
-
-
Volatility
0.21%, 0.73%
Prev Close
4.6%
Price
7.165
Change
-1.85%
Company Profile
- Volume Average 280.8K
- Market Capitalization 420.08M
- Employee 157
- CEO Dr. Michel Detheux Ph.D.
- Headquarters Cambridge,MA,US
- IPO Date 2020-07-24
-
Website
https://www.iteostherapeutics.com 
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
